Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
28 July 2021Website:
http://www.staterabiopharma.comNext earnings report:
25 July 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Fri, 28 Jun 2024 13:30:00 GMTDividend
Analysts recommendations
Institutional Ownership
STAB Latest News
21 June 2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. INFOPRO DIGITAL Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 12th June 2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
03/06/2024 Not for distribution, directly or indirectly, in or into the United States or any jurisdiction in which such distribution would be unlawful. BERTRAND FRANCHISE FINANCE S.A.S Post-stabilisation Period Announcement NO STABILISATION CARRIED OUT [Further to the pre-stabilisation period announcement dated 30/05/2024 BNP Paribas (contact: Stanford Hartman telephone: 0207 595 8222) hereby gives notice that no stabilisation (within the meaning of Article 3.2(d) of the Market Abuse Regulation (EU/596/2014)) was undertaken by the Stabilisation Manager(s) named below in relation to the offer of the following securities.
What type of business is Statera Biopharma?
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.
What sector is Statera Biopharma in?
Statera Biopharma is in the Healthcare sector
What industry is Statera Biopharma in?
Statera Biopharma is in the Biotechnology industry
What country is Statera Biopharma from?
Statera Biopharma is headquartered in United States
When did Statera Biopharma go public?
Statera Biopharma initial public offering (IPO) was on 28 July 2021
What is Statera Biopharma website?
https://www.staterabiopharma.com
Is Statera Biopharma in the S&P 500?
No, Statera Biopharma is not included in the S&P 500 index
Is Statera Biopharma in the NASDAQ 100?
No, Statera Biopharma is not included in the NASDAQ 100 index
Is Statera Biopharma in the Dow Jones?
No, Statera Biopharma is not included in the Dow Jones index
When does Statera Biopharma report earnings?
The next expected earnings date for Statera Biopharma is 25 July 2024